| 晚期非小细胞肺癌个体化化疗的研究进展 |
| |
| 引用本文： | 王丽.晚期非小细胞肺癌个体化化疗的研究进展[J].世界临床药物,2012,33(4):193-196. |
| |
| 作者姓名： | 王丽 |
| |
| 作者单位： | 王丽 (同济大学附属上海市肺科医院肿瘤科,上海,200433) ； |
| |
| 摘 要： | 非小细胞肺癌(NSCLC)全球发病率高、死亡病例多。第三代化疗药物(长春瑞滨、吉西他滨、紫杉醇、多西他赛)联合铂类的两药化疗方案仍是目前NSCLC一线治疗的常规方案。与化疗疗效相关的新靶标基因(切除修复交叉互补基因1与铂类耐药、核苷酸还原酶调节因子1与吉西他滨耐药、β微管蛋白与紫杉类耐药等)有可能作为预测化疗反应的生物标记。本文结合分子病理分型综述临床个体化化疗方案研究。
|
| 关 键 词： | 非小细胞肺癌 个体化 药物疗法 |
Research progress of non-small cell lung cancer individualized chemotherapy |
| |
| WANG Li.Research progress of non-small cell lung cancer individualized chemotherapy[J].WORLD CLINICAL DRUGS,2012,33(4):193-196. |
| |
| Authors: | WANG Li |
| |
| Institution: | WANG Li(Department of Oncology,Shanghai Pulmonary Hospital,Tongji University,Shanghai 200433,China) |
| |
| Abstract: | Non-small cell lung cancer(NSCLC) is the malignant tumor with the highest incidence and mortality.The combination of the third generation of chemotherapy drugs(vinorelbine,gemcitabine,paclitaxel,docetaxel) with platinum-based drugs so far has been the common practice of NSCLC first-line treatment.New target genes related to chemotherapeutic effect(ERCC-1 and platinum-based resistance,RRM-1 and gemcitabine resistance,β-tubulin and paclitaxel resistance) are of the potential to be the biomarker of predicting chemotherapy reaction.This review describes integration of molecular pathological types and individualized chemotherapy. |
| |
| Keywords: | non-small cell lung cancer individuation drug therapy |
| 本文献已被 CNKI 等数据库收录！ |
